Literature DB >> 23814484

Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.

João D Barros-Silva1, Paula Paulo, Anne Cathrine Bakken, Nuno Cerveira, Marthe Løvf, Rui Henrique, Carmen Jerónimo, Ragnhild A Lothe, Rolf Inge Skotheim, Manuel R Teixeira.   

Abstract

Gene fusions involving the erythroblast transformation-specific (ETS) transcription factors ERG, ETV1, ETV4, ETV5, and FLI1 are a common feature of prostate carcinomas (PCas). The most common upstream fusion partner described is the androgen-regulated prostate-specific gene TMPRSS2, most frequently with ERG, but additional 5' fusion partners have been described. We performed 5' rapid amplification of cDNA ends in 18 PCas with ETV1, ETV4, or ETV5 outlier expression to identify the 5' fusion partners. We also evaluated the exon-level expression profile of these ETS genes in 14 cases. We identified and confirmed by fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction the two novel chimeric genes OR51E2-ETV1 and UBTF-ETV4 in two PCas. OR51E2 encodes a G-protein-coupled receptor that is overexpressed in PCas, whereas UBTF is a ubiquitously expressed gene encoding an HMG-box DNA-binding protein involved in ribosome biogenesis. We additionally describe two novel gene fusion combinations of previously described genes, namely, SLC45A3-ETV4 and HERVK17-ETV4. Finally, we found one PCa with TMPRSS2-ETV1, one with C15orf21-ETV1, one with EST14-ETV1, and two with 14q133-q21.1-ETV1. In nine PCas (eight ETV1 and one ETV5), exhibiting ETS outlier expression and genomic rearrangement detected by FISH, no 5' fusion partner was found. Our findings contribute significantly to characterize the heterogeneous group of ETS gene fusions and indicate that all genes described as 5' fusion partners with one ETS gene can most likely be rearranged with any of the other ETS genes involved in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23814484      PMCID: PMC3689235          DOI: 10.1593/neo.13232

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  27 in total

1.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Saravana M Dhanasekaran; Beth E Helgeson; Xuhong Cao; David S Morris; Anjana Menon; Xiaojun Jing; Qi Cao; Bo Han; Jindan Yu; Lei Wang; James E Montie; Mark A Rubin; Kenneth J Pienta; Diane Roulston; Rajal B Shah; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Nature       Date:  2007-08-02       Impact factor: 49.962

2.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

3.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Authors:  Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

4.  c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I.

Authors:  Carla Grandori; Natividad Gomez-Roman; Zoe A Felton-Edkins; Celine Ngouenet; Denise A Galloway; Robert N Eisenman; Robert J White
Journal:  Nat Cell Biol       Date:  2005-03       Impact factor: 28.824

5.  Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors.

Authors:  Jinsheng Weng; Wenbin Ma; Dianne Mitchell; Jianshe Zhang; Mingyao Liu
Journal:  J Cell Biochem       Date:  2005-12-01       Impact factor: 4.429

6.  PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

Authors:  L L Xu; B G Stackhouse; K Florence; W Zhang; N Shanmugam; I A Sesterhenn; Z Zou; V Srikantan; M Augustus; V Roschke; K Carter; D G McLeod; J W Moul; D Soppett; S Srivastava
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

7.  Molecular cloning of the RNA polymerase I transcription factor hUBF/NOR-90 (UBTF) gene and localization to 17q21.3 by fluorescence in situ hybridization and radiation hybrid mapping.

Authors:  A G Matera; W Wu; H Imai; C L O'Keefe; E K Chan
Journal:  Genomics       Date:  1997-04-01       Impact factor: 5.736

8.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Localization of the human RNA polymerase I transcription factor gene (UBTF) to the D17S183 locus on chromosome 17q21 and construction of a long-range restriction map of the region.

Authors:  K A Jones; D M Black; B L Griffiths; E Solomon
Journal:  Genomics       Date:  1995-12-10       Impact factor: 5.736

10.  Three-dimensional genome architecture influences partner selection for chromosomal translocations in human disease.

Authors:  Jesse M Engreitz; Vineeta Agarwala; Leonid A Mirny
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

View more
  15 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia.

Authors:  S Velaeti; E Dimitriadis; K Kontogianni-Katsarou; A Savvani; E Sdrolia; G Pantazi; S Stefanakis; T Trangas; N Pandis; K Petraki
Journal:  Tumour Biol       Date:  2014-06-25

Review 3.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

4.  ChimeRScope: a novel alignment-free algorithm for fusion transcript prediction using paired-end RNA-Seq data.

Authors:  You Li; Tayla B Heavican; Neetha N Vellichirammal; Javeed Iqbal; Chittibabu Guda
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

5.  Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.

Authors:  Torfinn Nome; Gard Os Thomassen; Jarle Bruun; Terje Ahlquist; Anne C Bakken; Andreas M Hoff; Torleiv Rognum; Arild Nesbakken; Susanne Lorenz; Jinchang Sun; João Diogo Barros-Silva; Guro E Lind; Ola Myklebost; Manuel R Teixeira; Leonardo A Meza-Zepeda; Ragnhild A Lothe; Rolf I Skotheim
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

6.  Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.

Authors:  Marie Passet; Rathana Kim; Stéphanie Gachet; François Sigaux; Julie Chaumeil; Ava Galland; Thomas Sexton; Samuel Quentin; Lucie Hernandez; Lise Larcher; Hugo Bergugnat; Tao Ye; Nezih Karasu; Aurélie Caye; Beate Heizmann; Isabelle Duluc; Patrice Chevallier; Philippe Rousselot; Françoise Huguet; Thibaut Leguay; Mathilde Hunault; Françoise Pflumio; Jean-Noël Freund; Camille Lobry; Véronique Lhéritier; Hervé Dombret; Claire Domon-Dell; Jean Soulier; Nicolas Boissel; Emmanuelle Clappier
Journal:  Blood       Date:  2022-06-16       Impact factor: 25.476

7.  Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN.

Authors:  Xiaoyu Qu; Cecilia Yeung; Ilsa Coleman; Peter S Nelson; Min Fang
Journal:  Cancer Genet       Date:  2020-03-07

8.  Conference report from the 2015 OECI Oncology Days, Portugal, 22-24 June-tumour heterogeneity and next generation sequencing: morphology and technology.

Authors:  Linda Cairns
Journal:  Ecancermedicalscience       Date:  2015-08-19

9.  Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.

Authors:  Diana Mesquita; João D Barros-Silva; Joana Santos; Rolf I Skotheim; Ragnhild A Lothe; Paula Paulo; Manuel R Teixeira
Journal:  Oncotarget       Date:  2015-03-10

10.  Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.

Authors:  Bushra Ateeq; Lakshmi P Kunju; Shannon L Carskadon; Swaroop K Pandey; Geetika Singh; Immanuel Pradeep; Vini Tandon; Atin Singhai; Apul Goel; Sonal Amit; Asha Agarwal; Amit K Dinda; Amlesh Seth; Alexander Tsodikov; Arul M Chinnaiyan; Nallasivam Palanisamy
Journal:  Prostate       Date:  2015-03-23       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.